Why the study?
Do triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants reduce the risk of coronary heart disease?
Do triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants reduce the risk of coronary heart disease?
The clinical benefit of lowering triglyceride and LDL-C levels appears to be proportional to the absolute change in ApoB.
May support ApoB as key mediator of CHD benefit from lipid lowering; extends genetic evidence but requires prospective confirmation.
Triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants were associated with similar lower risk of CHD per unit difference in ApoB. Therefore, the clinical benefit of lowering triglyceride and LDL-C levels may be proportional to the absolute change in ApoB.
No takes yet. Share an insight, caveat, or question.
Ference et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: